186 results on '"Shiew-Mei Huang"'
Search Results
2. Evaluating Pneumonitis Incidence in Patients with Non–small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data
- Author
-
Qi Liu, Chenan Zhang, Yue Huang, Ruihao Huang, Shiew-Mei Huang, Erin Larkins, Liza Stapleford, Donna R. Rivera, Paul G. Kluetz, Shenggang Wang, Hao Zhu, James Weese, Elizabeth Cromartie, Mahder Teka, Sheetal Walters, Frank Wolf, and Thomas D. Brown
- Abstract
Pneumonitis is a potentially life-threatening complication of anticancer therapy, and future treatment decisions may be informed by characterizing patients receiving therapies in the real-world setting. In this study, the incidence of treatment-associated pneumonitis (TAP) was compared among patients with advanced non–small cell lung cancer receiving immune checkpoint inhibitors (ICI) or chemotherapies in either of two settings: randomized clinical trials (RCT) or real world data (RWD)-based clinical practice. Pneumonitis cases were identified using International Classification of Diseases codes (for RWD), or the Medical Dictionary for Regulatory Activities preferred terms (for RCTs). TAP was defined as pneumonitis diagnosed during treatment or within 30 days of the last treatment administration. Overall TAP rates in the RWD cohort were lower [ICI: 1.9%; 95% confidence interval (CI), 1.2–3.2; chemotherapy: 0.8%; 95% CI, 0.4–1.6] than overall rates in the RCT cohort (ICI: 5.6%; 95% CI, 5.0–6.2; chemotherapy: 1.2%; 95% CI, 0.9–1.5). Overall RWD TAP rates were similar to grade 3+ RCT TAP rates (ICI: 2.0%; 95% CI, 1.6–2.3; chemotherapy: 0.6%; 95% CI, 0.4–0.9). In both cohorts, higher TAP incidence was observed among patients with a past medical history of pneumonitis than those without, regardless of treatment group. On the basis of this sizable study leveraging RWD, TAP incidence was low in the RWD cohort, likely in part due to methodology used for RWD focusing on clinically significant cases. Past medical history of pneumonitis was associated with TAP in both cohorts.Significance:Pneumonitis is a potentially life-threatening complication of anticancer treatment. As treatment options expand, management decisions become increasingly complex, and there is a greater need to understand the safety profiles of the treatment options in the real-world setting. Real-world data serve as an additional source of valuable information to complement clinical trial data and inform understanding of toxicity in patients with non–small cell lung cancer receiving ICIs or chemotherapies.
- Published
- 2023
3. Impact of Organ Impairment on the Pharmacokinetics of Therapeutic Peptides and Proteins
- Author
-
Elimika Pfuma Fletcher, Martina Sahre, Yuen Yi Hon, Anand Balakrishnan, Lin Zhou, Qin Sun, Jie Wang, Kimberly Maxfield, Raajan Naik, Shiew Mei Huang, and Yow-Ming C. Wang
- Subjects
Pharmaceutical Science - Published
- 2023
4. Data from Evaluating Pneumonitis Incidence in Patients with Non–small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data
- Author
-
Thomas D. Brown, Frank Wolf, Sheetal Walters, Mahder Teka, Elizabeth Cromartie, James Weese, Hao Zhu, Shenggang Wang, Paul G. Kluetz, Donna R. Rivera, Liza Stapleford, Erin Larkins, Shiew-Mei Huang, Ruihao Huang, Yue Huang, Chenan Zhang, and Qi Liu
- Abstract
Pneumonitis is a potentially life-threatening complication of anticancer therapy, and future treatment decisions may be informed by characterizing patients receiving therapies in the real-world setting. In this study, the incidence of treatment-associated pneumonitis (TAP) was compared among patients with advanced non–small cell lung cancer receiving immune checkpoint inhibitors (ICI) or chemotherapies in either of two settings: randomized clinical trials (RCT) or real world data (RWD)-based clinical practice. Pneumonitis cases were identified using International Classification of Diseases codes (for RWD), or the Medical Dictionary for Regulatory Activities preferred terms (for RCTs). TAP was defined as pneumonitis diagnosed during treatment or within 30 days of the last treatment administration. Overall TAP rates in the RWD cohort were lower [ICI: 1.9%; 95% confidence interval (CI), 1.2–3.2; chemotherapy: 0.8%; 95% CI, 0.4–1.6] than overall rates in the RCT cohort (ICI: 5.6%; 95% CI, 5.0–6.2; chemotherapy: 1.2%; 95% CI, 0.9–1.5). Overall RWD TAP rates were similar to grade 3+ RCT TAP rates (ICI: 2.0%; 95% CI, 1.6–2.3; chemotherapy: 0.6%; 95% CI, 0.4–0.9). In both cohorts, higher TAP incidence was observed among patients with a past medical history of pneumonitis than those without, regardless of treatment group. On the basis of this sizable study leveraging RWD, TAP incidence was low in the RWD cohort, likely in part due to methodology used for RWD focusing on clinically significant cases. Past medical history of pneumonitis was associated with TAP in both cohorts.Significance:Pneumonitis is a potentially life-threatening complication of anticancer treatment. As treatment options expand, management decisions become increasingly complex, and there is a greater need to understand the safety profiles of the treatment options in the real-world setting. Real-world data serve as an additional source of valuable information to complement clinical trial data and inform understanding of toxicity in patients with non–small cell lung cancer receiving ICIs or chemotherapies.
- Published
- 2023
5. Supplementary Tables 1-6 from Evaluating Pneumonitis Incidence in Patients with Non–small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data
- Author
-
Thomas D. Brown, Frank Wolf, Sheetal Walters, Mahder Teka, Elizabeth Cromartie, James Weese, Hao Zhu, Shenggang Wang, Paul G. Kluetz, Donna R. Rivera, Liza Stapleford, Erin Larkins, Shiew-Mei Huang, Ruihao Huang, Yue Huang, Chenan Zhang, and Qi Liu
- Abstract
Supplementary Table 1. Pneumonitis defined using A) ICD-9 and B) ICD-10 codes that included ‘pneumonitis’ or associated concepts in the Unified Medical Language System, with Bidirectional General Equivalence Mappings used to identify equivalent terms between ICD-9 and ICD-10 in the Real World Data (RWD) cohortSupplementary Table 2: ICD codes used to identify history of chronic lung condition in the Real World Data (RWD) cohortSupplementary Table 3. Selection of clinical trial (RCT) populationSupplementary Table 4. Incidence of Treatment-Associated Pneumonitis in the Randomized Clinical Trial (RCT) Cohort and the Real World Data (RWD) Cohort based on sensitivity analysesSupplementary Table 5. Treatment-associated pneumonitis counts by grade in the Randomized Clinical Trial (RCT) cohortSupplementary Table 6. Demographic and Clinical Characteristics of Patients With and Without Radiation Therapy (RT) status available in the Real World Data (RWD) Cohort
- Published
- 2023
6. Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades
- Author
-
Lei Zhang, Qi Liu, Shiew-Mei Huang, and Robert Lionberger
- Subjects
Pharmacology ,Special Section on New Era of Transporter Science: Unraveling the Functional Role of Orphan Transporters ,Pharmaceutical Science - Abstract
Transporters govern the access of molecules to cells or their exit from cells, thereby controlling the overall distribution of drugs to their intracellular site of action. Clinically relevant drug-drug interactions mediated by transporters are of increasing interest in drug development. Drug transporters, acting alone or in concert with drug metabolizing enzymes, can play an important role in modulating drug absorption, distribution, metabolism, and excretion, thus affecting the pharmacokinetics and/or pharmacodynamics of a drug. Dr. Kathy Giacomini from the University of California, San Francisco is one of the world leaders in transporters and pharmacogenetics with key contributions to transporter science. Her contributions to transporter science are noteworthy. This review paper will summarize Dr. Giacomini’s key contributions and influence on transporters in regulatory science in the past two decades. Regulatory science research highlighted in this review covers various aspects of transporter science, including understanding the effect of renal impairment on transporters, transporter ontogeny, biomarkers for transporters, and interactions of excipients with transporters affecting drug absorption. SIGNIFICANCE STATEMENT: This review paper highlights Dr. Giacomini’s key contributions and influence on transporters in regulatory science in the past two decades. She has been at the cutting edge of science pertaining to drug transport, drug disposition, and regulatory science, leading to a new era of translational sciences pertaining to drug disposition and transporter biology. Her research has and will continue to bring enormous impact on gaining new knowledge in guiding drug development and inspire scientists from all sectors in the field.
- Published
- 2022
7. Roadmap to 2030 for Drug Evaluation in Older Adults
- Author
-
Jerry H. Gurwitz, Bindu Kanapuru, Rajanikanth Madabushi, Jamie Gamerman, Francesca Cerreta, Jack Cook, Robert M. Califf, Paul Goldsmith, Daphne Guinn, Sharon K. Inouye, Robert Temple, Janice B. Schwartz, Piet H. van der Graaf, Carolyn R. Cho, Munir Pirmohamed, Barbara Radziszewska, Patricia W. Slattum, Qi Liu, Sarah N. Hilmer, Shiew-Mei Huang, H. Keipp Talbot, Phil Posner, Gilbert J. Burckart, S.W. Johnny Lau, and Sebastian Haertter
- Subjects
Gerontology ,Aging ,Drug-Related Side Effects and Adverse Reactions ,Clinical Trials and Supportive Activities ,Population ,MEDLINE ,law.invention ,Clinical Research ,law ,Prevalence ,Humans ,Medicine ,Pharmacology (medical) ,Pharmacology & Pharmacy ,Dosing ,education ,Adverse effect ,Aged ,Pharmacology ,Polypharmacy ,education.field_of_study ,Clinical pharmacology ,business.industry ,Evaluation of treatments and therapeutic interventions ,Pharmacology and Pharmaceutical Sciences ,Brain Disorders ,Clinical trial ,6.1 Pharmaceuticals ,Pharmacodynamics ,Drug Evaluation ,Patient Safety ,business - Abstract
Changes that accompany older age can alter the pharmacokinetics (PK), pharmacodynamics (PD), and likelihood of adverse effects (AEs) of a drug. However, older adults, especially the oldest or those with multiple chronic health conditions, polypharmacy, or frailty, are often under-represented in clinical trials of new drugs. Deficits in the current conduct of clinical evaluation of drugs for older adults and potential steps to fill those knowledge gaps are presented in this communication. The most important step is to increase clinical trial enrollment of older adults who are representative of the target treatment population. Unnecessary eligibility criteria should be eliminated. Physical and financial barriers to participation should be removed. Incentives could be created for inclusion of older adults. Enrollment goals should be established based on intended treatment indications, prevalence of the condition, and feasibility. Relevant clinical pharmacology data need to be obtained early enough to guide dosing and reduce risk for participation of older adults. Relevant PK and PD data as well as patient-centered outcomes should be measured during trials. Trial data should be analyzed for differences in PK, PD, effectiveness, and safety arising from differences in age or from the presence of conditions common in older adults. Postmarket evaluations with real-world evidence and drug labeling updates throughout the product lifecycle reflecting new knowledge are also needed. A comprehensive plan is needed to ensure adequate evaluation of the safety and effectiveness of drugs in older adults.
- Published
- 2021
8. Current Perspective on Residual Knowledge Gaps in the Assessment of Transporter‐Mediated Drug Interactions
- Author
-
Xinning Yang, Kellie Reynolds, Rajanikanth Madabushi, and Shiew‐Mei Huang
- Subjects
Cytochrome P-450 Enzyme Inducers ,Pharmacology ,Drug Development ,Humans ,Membrane Transport Proteins ,Drug Interactions ,Pharmacology (medical) - Abstract
Assessment of transporter-mediated drug-drug interaction (DDI) is integral to drug development. A risk-based approach leveraging in vitro, in vivo, and in silico information is used to evaluate the DDI liability of drugs and inform the instructions of use. While tremendous advances have been made in recent decades, there are knowledge gaps warranting further research. Herein, we focus on select areas to advance assessment of DDI potential for drugs as substrates, inhibitors, or inducers of certain transporters.
- Published
- 2022
9. Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision‐making—A workshop summary
- Author
-
Rajanikanth Madabushi, Daphney Jean, Paul Seo, Yaning Wang, Liang Zhao, Issam Zineh, Hao Zhu, Joseph A. Grillo, Yuching Yang, Xinyuan Zhang, Kimberly Bergman, Nina Isoherranen, Shiew-Mei Huang, Million A. Tegenge, Colleen Kuemmel, Stephen D. Hall, Kunal Naik, Ping Zhao, Jessica Benjamin, Lauren Milligan, and Fang Wu
- Subjects
Clinical pharmacology ,Computer science ,Management science ,Best practice ,Pharmacokinetic modeling ,RM1-950 ,Models, Biological ,law.invention ,Drug Development ,law ,Modeling and Simulation ,Pharmacology, Clinical ,Perspective ,Humans ,Computer Simulation ,Pharmacokinetics ,Pharmacology (medical) ,Therapeutics. Pharmacology ,Perspectives - Published
- 2021
10. More Than Pharmacokinetics: Transporters in Clinical Pharmacology
- Author
-
Kathleen M. Giacomini and Shiew Mei Huang
- Subjects
Pharmacology ,Pharmacology, Clinical ,Humans ,Membrane Transport Proteins ,Pharmacology (medical) ,Pharmacokinetics - Published
- 2022
11. Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018
- Author
-
Hristina Dimova, Shiew-Mei Huang, Isabelle Ragueneau-Majlessi, Xinning Yang, Claire Steinbronn, Nina Isoherranen, and Jingjing Yu
- Subjects
Drug ,Databases, Factual ,Metabolite ,media_common.quotation_subject ,Cmax ,Pharmacology ,Risk Assessment ,030226 pharmacology & pharmacy ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,In vivo ,Cytochrome P-450 Enzyme Inhibitors ,Humans ,Potency ,Drug Interactions ,Pharmacokinetics ,Pharmacology (medical) ,Biotransformation ,media_common ,biology ,Area under the curve ,Cytochrome P450 ,In vitro ,Liver ,Pharmaceutical Preparations ,chemistry ,Area Under Curve ,030220 oncology & carcinogenesis ,biology.protein - Abstract
Evaluating the potential of new drugs and their metabolites to cause drug-drug interactions (DDIs) is critical for understanding drug safety and efficacy. Although multiple analyses of proprietary metabolite testing data have been published, no systematic analyses of metabolite data collected according to current testing criteria have been conducted. To address this knowledge gap, 120 new molecular entities approved between 2013 and 2018 were reviewed. Comprehensive data on metabolite-to-parent area under the curve ratios (AUCM /AUCP ), inhibitory potency of parent and metabolites, and clinical DDIs were collected. Sixty-four percent of the metabolites quantified in vivo had AUCM /AUCP ≥ 0.25 and 75% of these metabolites were tested for cytochrome P450 (CYP) inhibition in vitro, resulting in 15 metabolites with potential DDI risk identification. Although 50% of the metabolites with AUCM /AUCP
- Published
- 2021
12. Model-Based Approach to Selecting Pegfilgrastim Dose for Pharmacokinetic and Pharmacodynamic Similarity Studies in Biosimilar Development
- Author
-
Fang Li, Qin Sun, Shengnan Du, Jeffry Florian, Yaning Wang, Shiew Mei Huang, Issam Zineh, and Yow‐Ming C. Wang
- Subjects
Pharmacology ,Pharmacology (medical) - Abstract
This study applied modeling and simulation (MS) approaches to evaluate the sensitivity of pegfilgrastim pharmacokinetics (PKs) and pharmacodynamics (PDs) to changes in dose amount, and linear or nonlinear clearance (CL) over pegfilgrastim subcutaneous dose of 2-6 mg. A previously published model was adapted to better describe pegfilgrastim PK and PD data in healthy subjects and used in simulation. Nonlinear CL accounts for 98% and 77%, respectively, of the total CL of pegfilgrastim at 2 and 6 mg. The sensitivity analyses showed: (i) PK of 2 and 6 mg doses are similarly sensitive to detect differences for a 5% change in dose; (ii) PK of 2 mg dose is more sensitive to changes in receptor binding affinity, a model parameter for nonlinear CL, and a product quality attribute characterized with orthogonal methods as part of demonstrating analytical similarity between products; (iii) PK of approved 6 mg dose is more sensitive to changes in linear CL, which has not been associated with any specific product quality attributes, and (iv) the PDs are not sensitive to changes in linear or nonlinear CL. Taken together, our analyses support that the approved pegfilgrastim dose of 6 mg is appropriate for detecting differences between a biosimilar and the reference products in pegfilgrastim PK and PD similarity studies. The described MS approaches can be adopted to support dose selection for biosimilars with nonlinear PK and complex PK-PD interplay.
- Published
- 2022
13. Landscape Analysis of the Application of Artificial Intelligence and Machine Learning in Regulatory Submissions for Drug Development From 2016 to 2021
- Author
-
Qi Liu, Ruihao Huang, Julie Hsieh, Hao Zhu, Mo Tiwari, Guansheng Liu, Daphney Jean, M. Khair ElZarrad, Tala Fakhouri, Steven Berman, Billy Dunn, Matthew C. Diamond, and Shiew‐Mei Huang
- Subjects
Pharmacology ,Pharmacology (medical) - Published
- 2022
14. Contributors
- Author
-
Darrell R. Abernethy, Balaji Agoram, John M. Allen, Mark E. Arnold, Arthur J. Atkinson, Thomas J. Bateman, Kimberly Bergman, Brian Booth, David W. Boulton, Robert A. Branch, Gilbert J. Burckart, Mary Buschmann, Owen Carmichael, Christine Chamberlain, Ligong Chen, Charles E. Daniels, Promi Das, Jana G. Delfino, John N. Van Den Anker, Albert W. Dreisbach, Michael Dyszel, Justin C. Earp, M. Khair ElZarrad, Osatohanmwen J. Enogieru, Elimika Pfuma Fletcher, David M. Foster, Marilynn C. Frederiksen, Aleksandra Galetin, Pamela D. Garzone, Kathleen M. Giacomini, Megan A. Gibbs, Jack A Gilbert, Danijela Gnjidic, Charles T. Gombar, Denis M. Grant, Charles Grudzinskas, Bengt Hamren, Nicholas H.G. Holford, Shiew-Mei Huang, Renee Iacona, Nina Isoherranen, Denise Jin, Bridgette L. Jones, Gregory L. Kearns, Cindy Kortepeter, Elizabeth Kunkoski, S.W. Johnny Lau, Christopher Leptak, Juan J.L. Lertora, Lawrence J. Lesko, Jiang Liu, Qi Liu, Rajanikanth Madabushi, Raymond Miller, Diane R. Mould, Monica Muñoz, Thomas D. Nolin, Robert Joseph Noveck, R. Scott Obach, Michael Pacanowski, Mary F. Paine, Carl C. Peck, Anuradha Ramamoorthy, A. David Rodrigues, Malcolm Rowland, Chandrahas G. Sahajwalla, Martina Dagmar Sahre, Robert N. Schuck, Khushboo Sharma, Tristan Sissung, Catherine S. Stika, Chris H. Takimoto, Helen Tomkinson, Jack Uetrecht, Paolo Vicini, Karen D. Vo, John A. Wagner, Yaning Wang, Yow-Ming C. Wang, Peter G. Wells, Michael J. Wick, Sook Wah Yee, Ophelia Yin, Nathalie K. Zgheib, Lei Zhang, and Hao Zhu
- Published
- 2022
15. Mechanisms and genetics of drug transport
- Author
-
Lei Zhang, Osatohanmwen J. Enogieru, Sook Wah Yee, Shiew-Mei Huang, and Kathleen M. Giacomini
- Published
- 2022
16. The role of the FDA in guiding drug development
- Author
-
Elimika Pfuma Fletcher, Rajanikanth Madabushi, Chandrahas G. Sahajwalla, Lawrence J. Lesko, and Shiew-Mei Huang
- Published
- 2022
17. Drug-drug interactions
- Author
-
Aleksandra Galetin, Lei Zhang, A. David Rodrigues, and Shiew-Mei Huang
- Published
- 2022
18. Emerging clinical pharmacology topics in drug development and precision medicine
- Author
-
Mary M. Buschmann, Shiew-Mei Huang, Hao Zhu, Promi Das, Kimberly Bergman, Elizabeth Kunkoski, M. Khair ElZarrad, Qi Liu, and Jack A. Gilbert
- Subjects
medicine.medical_specialty ,Clinical pharmacology ,business.industry ,Treatment outcome ,Precision medicine ,Digital health ,law.invention ,Drug development ,law ,medicine ,Medical physics ,Microbiome ,business ,Drug effect - Abstract
Science is constantly evolving. As a result, novel tools as well as new issues are arising for clinical pharmacologists. In this chapter, we will discuss some emerging topics in clinical pharmacology, including model-informed drug development, real-world data and real-world evidence, and digital health technologies, as well as the microbiome and its impact on drug effect and treatment outcome.
- Published
- 2022
19. Regulatory Efforts to Facilitate Evaluation and Clinical Management of Drug‐Drug Interaction Risks
- Author
-
Xinning Yang, Rajanikanth Madabushi, Issam Zineh, Elimika Pfuma Fletcher, and Shiew-Mei Huang
- Subjects
Pharmacology ,medicine.medical_specialty ,United States Food and Drug Administration ,business.industry ,Drug-drug interaction ,MEDLINE ,United States ,Pharmaceutical Preparations ,Humans ,Medicine ,Drug Interactions ,Pharmacology (medical) ,Precision Medicine ,business ,Intensive care medicine - Published
- 2020
20. Dosing Recommendations for Pediatric Patients With Renal Impairment
- Author
-
Caitlyn Young, Jian Wang, Mona Khurana, Daijha J.C. Anderson, Shiew-Mei Huang, Gilbert J. Burckart, Amer Al-khouja, and Kyunghun Park
- Subjects
Drug ,medicine.medical_specialty ,Prescription Drugs ,Special populations ,Databases, Factual ,media_common.quotation_subject ,Formularies as Topic ,urologic and male genital diseases ,Pediatrics ,030226 pharmacology & pharmacy ,Article ,Clinical study ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Medicine ,Drug Dosage Calculations ,Pharmacology (medical) ,Renal Insufficiency ,Dosing ,Child ,Intensive care medicine ,Drug toxicity ,Drug Labeling ,media_common ,Pharmacology ,Evidence-Based Medicine ,United States Food and Drug Administration ,business.industry ,United States ,Drug development ,Clinical evidence ,030220 oncology & carcinogenesis ,Drug Information Services ,Practice Guidelines as Topic ,business ,Clearance - Abstract
A treatment gap exists for pediatric patients with renal impairment. Alterations in renal clearance and metabolism of drugs render standard dosage regimens inappropriate and may lead to drug toxicity, but these studies are not routinely conducted during drug development. The objective of this study was to examine the clinical evidence behind current renal impairment dosage recommendations for pediatric patients in a standard pediatric dosing handbook. The sources of recommendations and comparisons included the pediatric dosing handbook (Lexicomp), the U.S. Food and Drug Administration-approved manufacturer’s labels, and published studies in the literature. One hundred twenty-six drugs in Lexicomp had pediatric renal dosing recommendations. Only 14% (18 of 126) of Lexicomp pediatric renal dosing recommendations referenced a pediatric clinical study, and 15% of manufacturer’s labels (19 of 126) described specific dosing regimens for renally impaired pediatric patients. Forty-two products had published information on pediatric renal dosing, but 19 (45%) were case studies. When pediatric clinical studies were not referenced in Lexicomp, the renal dosing recommendations followed the adult and pediatric dosing recommendations on the manufacturer’s label. Clinical evidence in pediatric patients does not exist for most renal dosing recommendations in a widely used pediatric dosing handbook, and the adult renal dosing recommendations from the manufacturer’s label are currently the primary source of pediatric renal dosing information.
- Published
- 2020
21. Application of Machine Learning in Drug Development and Regulation: Current Status and Future Potential
- Author
-
Gideon M. Blumenthal, Qi Liu, Shiew-Mei Huang, Yaning Wang, M. Khair ElZarrad, Chao Liu, Daphney Jean, and Hao Zhu
- Subjects
Pharmacology ,business.industry ,Computer science ,MEDLINE ,Data science ,Machine Learning ,Text mining ,Drug Development ,Drug development ,Drug and Narcotic Control ,Humans ,Pharmacology (medical) ,Current (fluid) ,business ,Forecasting - Published
- 2020
22. Toward Bridging Unmet Medical Need in Early Alzheimer's Disease: An Evaluation of Beta-Amyloid (Aβ) Plaque Burden as a Potential Drug Development Tool
- Author
-
Hao Zhu, Mehul Mehta, Shiew‐Mei Huang, and Yaning Wang
- Subjects
Pharmacology ,Disease Models, Animal ,Amyloid beta-Peptides ,Drug Development ,Alzheimer Disease ,Animals ,Brain ,Humans ,Pharmacology (medical) ,Plaque, Amyloid - Published
- 2021
23. Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019
- Author
-
S W Johnny, Lau, Yue, Huang, Julie, Hsieh, Shenggang, Wang, Qi, Liu, Patricia W, Slattum, Janice B, Schwartz, Shiew-Mei, Huang, and Robert, Temple
- Subjects
Heart Failure ,Biological Products ,Clinical Trials as Topic ,Lung Neoplasms ,General Medicine ,Stroke ,Cross-Sectional Studies ,Diabetes Mellitus, Type 2 ,Carcinoma, Non-Small-Cell Lung ,Sleep Initiation and Maintenance Disorders ,Atrial Fibrillation ,Humans ,Osteoporosis ,Patient Participation ,Aged - Abstract
ImportanceOlder age may be accompanied by changes in the pharmacokinetics or pharmacodynamics or both of medications that can result in altered safety and efficacy profiles.ObjectiveTo assess representation of older adults in clinical trials of new drug applications (NDAs) and biologics license applications (BLAs).Design, Setting, and ParticipantsThis cross-sectional study analyzed US Food and Drug Administration (FDA) data for NDAs and BLAs approved from 2010 through 2019. Age distribution of clinical trial participants was compared with age distribution of the US population with the disease or disorder (prevalent population). Data were from adults enrolled in registration trials for depression, heart failure, insomnia, non–small cell lung cancer (NSCLC), nonvalvular atrial fibrillation (NVAF) stroke prevention, osteoporosis, and type 2 diabetes or adults sampled from US prevalent population in community-dwelling health data. Data were analyzed from November 2020 to February 2021.ExposuresTrial enrollment.Main Outcomes and MeasuresRepresentativeness of trial populations was assessed by the participation to prevalence ratio (PPR) defined as the percentage of patients by age group among clinical trial participants to the percentage of patients by age group among US prevalent population.ResultsData from 166 clinical trials (229 558 participants) for 44 NDAs and BLAs were analyzed. The most consistent finding was the limited enrollment of the oldest age groups, namely those 75 years and above for type 2 diabetes and NSCLC, and 80 years and above for NVAF stroke prevention, insomnia, heart failure, and osteoporosis. Adults aged 60 to 74 years were enrolled in equal or greater proportion than the US prevalent population.Conclusions and RelevanceIn this cross-sectional study, underrepresentation of the oldest adults existed during evaluation of new drugs and biologics, yet the older adults may represent significant proportions of the treatment population. Closing the representation gap between clinical trial enrollment and potential treatment populations is essential for safe and effective use of new drugs and biologics.
- Published
- 2022
24. A survey of pharmacokinetic bioanalytical methods in biosimilar biological license applications for the assessment of target and antidrug antibody effects
- Author
-
Yow-Ming C Wang, Theingi M. Thway, Shiew-Mei Huang, and Dana T Hackel
- Subjects
Bioanalysis ,business.industry ,Antidrug antibody ,Clinical Biochemistry ,Therapeutic protein ,Biosimilar ,General Medicine ,Pharmacology ,Method development ,Antibodies ,Analytical Chemistry ,Medical Laboratory Technology ,Pharmacokinetics ,Drug Discovery ,Medicine ,Humans ,General Pharmacology, Toxicology and Pharmaceutics ,business ,License ,Biosimilar Pharmaceuticals - Abstract
The presence of circulating targets and antidrug antibodies can influence the ability of a bioanalytical method to measure therapeutic protein (TP) concentration relevant to exposure-response evaluations. This project surveyed biosimilar submissions for their bioanalytical methods. Survey results revealed that 97% of pharmacokinetic methods designed to measure theoretically free or partial-free TPs with respect to target indeed measured free or partial-free TPs when considering experimental testing results for target effects. Antidrug antibody effect is less often evaluated. The observed trend of measuring biologically active forms of TP is consistent with the scientific understanding that pharmacokinetics of biologically active forms is more likely to be relevant to the clinical responses and evaluation of clinically meaningful differences to contribute to biosimilarity assessments.
- Published
- 2021
25. Anti-SARS-CoV-2 Repurposing Drug Database: Clinical Pharmacology Considerations
- Author
-
Xinyuan Zhang, Yaning Wang, Jiang Liu, James L. Weaver, Jianghong Fan, Hao Zhu, Kellie S. Reynolds, Eliford Kitabi, Guansheng Liu, Yuching Yang, Shiew-Mei Huang, Manuela Grimstein, Ying-Hong Wang, and Justin C. Earp
- Subjects
Drug ,Databases, Pharmaceutical ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,media_common.quotation_subject ,RM1-950 ,computer.software_genre ,Antiviral Agents ,law.invention ,Pharmacokinetics ,law ,In vivo ,Mini‐review ,Medicine ,Humans ,Pharmacology (medical) ,Repurposing ,media_common ,Data source ,Clinical pharmacology ,Database ,business.industry ,SARS-CoV-2 ,fungi ,Mini‐reviews ,Drug Repositioning ,In vitro ,Modeling and Simulation ,Therapeutics. Pharmacology ,business ,computer - Abstract
A critical step to evaluate the potential in vivo antiviral activity of a drug is to connect the in vivo exposure to its in vitro antiviral activity. The Anti–SARS‐CoV‐2 Repurposing Drug Database is a database that includes both in vitro anti–SARS‐CoV‐2 activity and in vivo pharmacokinetic data to facilitate the extrapolation from in vitro antiviral activity to potential in vivo antiviral activity for a large set of drugs/compounds. In addition to serving as a data source for in vitro anti–SARS‐CoV‐2 activity and in vivo pharmacokinetic information, the database is also a calculation tool that can be used to compare the in vitro antiviral activity with in vivo drug exposure to identify potential anti–SARS‐CoV‐2 drugs. Continuous development and expansion are feasible with the public availability of this database.
- Published
- 2021
26. A Change in Bile Flow: Looking Beyond Transporter Inhibition in the Development of Drug-induced Cholestasis
- Author
-
Lei Zhang, Shiew-Mei Huang, Brandy Garzel, and Hongbing Wang
- Subjects
Drug ,medicine.drug_class ,media_common.quotation_subject ,Clinical Biochemistry ,Pharmacology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Cholestasis ,hemic and lymphatic diseases ,medicine ,Animals ,Bile ,Humans ,ATP Binding Cassette Transporter, Subfamily B, Member 11 ,030304 developmental biology ,media_common ,Liver injury ,0303 health sciences ,Bile acid ,business.industry ,Transporter ,medicine.disease ,Bile Salt Export Pump ,Vesicular transport protein ,030220 oncology & carcinogenesis ,Farnesoid X receptor ,Chemical and Drug Induced Liver Injury ,business ,circulatory and respiratory physiology - Abstract
Background:Drug-induced Liver Injury (DILI) has received increasing attention over the past decades, as it represents the leading cause of drug failure and attrition. One of the most prevalent and severe forms of DILI involves the toxic accumulation of bile acids in the liver, known as Drug-induced Cholestasis (DIC). Traditionally, DIC is studied by exploring the inhibition of hepatic transporters such as Bile Salt Export Pump (BSEP) and multidrug resistance-associated proteins, predominantly through vesicular transport assays. Although this approach has identified numerous drugs that alter bile flow, many DIC drugs do not demonstrate prototypical transporter inhibition, but rather are associated with alternative mechanisms.Methods:We undertook a focused literature search on DIC and biliary transporters and analyzed peer-reviewed publications over the past two decades or so.Results:We have summarized the current perception regarding DIC, biliary transporters, and transcriptional regulation of bile acid homeostasis. A growing body of literature aimed to identify alternative mechanisms in the development of DIC has been evaluated. This review also highlights current in vitro approaches used for prediction of DIC.Conclusion:Efforts have continued to focus on BSEP, as it is the primary route for hepatic biliary clearance. In addition to inhibition, drug-induced BSEP repression or the combination of these two has emerged as important alternative mechanisms leading to DIC. Furthermore, there has been an evolution in the approaches to studying DIC including 3D cell cultures and computational modeling.
- Published
- 2019
27. Model‐Informed Drug Development: Current US Regulatory Practice and Future Considerations
- Author
-
Rajanikanth Madabushi, Qi Liu, Hao Zhu, Issam Zineh, Shiew-Mei Huang, and Yaning Wang
- Subjects
Pharmacology ,Evidence-Based Medicine ,Technology Assessment, Biomedical ,Knowledge management ,Scope (project management) ,Computer science ,Process (engineering) ,business.industry ,Clinical study design ,Decision Making ,MEDLINE ,030226 pharmacology & pharmacy ,Variety (cybernetics) ,03 medical and health sciences ,0302 clinical medicine ,Drug Development ,Drug development ,Dose optimization ,030220 oncology & carcinogenesis ,Humans ,Pharmacology (medical) ,business ,Prescription Drug User Fee Act - Abstract
Model-informed drug development (MIDD) refers to the application of a wide range of quantitative models in drug development to facilitate the decision-making process. MIDD was formally recognized in Prescription Drug User Fee Act (PDUFA) VI. There have been many regulatory applications of MIDD to address a variety of drug development and regulatory questions. These applications can be broadly classified into four categories: dose optimization, supportive evidence for efficacy, clinical trial design, and informing policy. Case studies, literature papers, and published regulatory documents are reviewed in this article to highlight some common features of these applications in each category. In addition to the further development and investment in these established domains of application, new technology, and areas, such as more mechanistic models, neural network models, and real-world data/evidence, are gaining attention, and more submissions and experiences are being accumulated to expand the application of model-based analysis to a wider scope.
- Published
- 2019
28. Fifty-Eight Years and Counting: High-Impact Publishing in Computational Pharmaceutical Sciences and Mechanism-Based Modeling
- Author
-
Johannes Khinast, Donald E. Mager, Christopher J. Roberts, Lian Yu, Christel A. S. Bergström, Shiew-Mei Huang, Bradley D. Anderson, Gerald B. Kasting, Filippos Kesisoglou, Joseph P. Balthasar, and Gregory E. Amidon
- Subjects
Publishing ,Engineering ,Drug Industry ,business.industry ,media_common.quotation_subject ,Computational Biology ,Pharmaceutical Science ,Mechanism based ,Library science ,02 engineering and technology ,021001 nanoscience & nanotechnology ,030226 pharmacology & pharmacy ,Biopharmaceutics ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Pharmaceutical sciences ,0210 nano-technology ,business ,Reputation ,media_common - Abstract
With this issue of the Journal of Pharmaceutical Sciences, we celebrate the nearly 6 decades of contributions to mechanistic-based modeling and computational pharmaceutical sciences. Along with its predecessor, The Journal of the American Pharmaceutical Association: Scientific Edition first published in 1911, JPharmSci has been a leader in the advancement of pharmaceutical sciences beginning with its inaugural edition in 1961. As one of the first scientific journals focusing on pharmaceutical sciences, JPharmSci has established a reputation for publishing high-quality research articles using computational methods and mechanism-based modeling. The journal's publication record is remarkable. With over 15,000 articles, 3000 notes, and more than 650 reviews from industry, academia, and regulatory agencies around the world, JPharmSci has truly been the leader in advancing pharmaceutical sciences.
- Published
- 2019
29. Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine: Current Status and Emerging Trends
- Author
-
Mitra Rocca, Qi Liu, Shiew-Mei Huang, and Mitra Ahadpour
- Subjects
Drug ,media_common.quotation_subject ,precision medicine ,Pharmaceutical Science ,Clinical science ,Pharmacy ,030226 pharmacology & pharmacy ,Models, Biological ,law.invention ,Translational Research, Biomedical ,03 medical and health sciences ,0302 clinical medicine ,Drug Development ,law ,Medicine ,Regulatory science ,Drug Approval ,media_common ,Clinical pharmacology ,business.industry ,United States Food and Drug Administration ,Precision medicine ,United States ,Drug development ,030220 oncology & carcinogenesis ,Pharmacology, Clinical ,Commentary ,regulatory science ,Engineering ethics ,clinical pharmacology ,Translational science ,business - Abstract
In the regulatory setting, clinical pharmacology focuses on the impact of intrinsic and extrinsic factors on inter-patient and intra-subject variability in drug exposure and response. This translational science contributes to the understanding of the benefit-risk profile in individual patients and the development of relevant therapeutic monitoring and management strategies. Clinical pharmacology also plays a major role in the development and qualification of drug development tools. This article presented some recent examples to illustrate the important roles of clinical pharmacology in drug development and evaluation. In addition, emerging trends in clinical pharmacology regulatory sciences were also discussed, including the Model-Informed Drug Development (MIDD) pilot program, the use of real-world data to generate real-world evidence, and leveraging advances in basic, biomedical, and clinical science into useful tools for drug development and evaluation. Continued advances in clinical pharmacology can be the basis of more rational and efficient drug development and improved access to new drug treatments that are tailored to the patient to achieve better efficacy and safety.
- Published
- 2020
30. Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting
- Author
-
Shiew-Mei Huang, Richard A. Graham, Jessica Benjamin, Andre Terzic, Gilbert J. Burckart, Aliza Thompson, Kellie S. Reynolds, Martina D. Sahre, Issam Zineh, Lauren Milligan, Robert N. Schuck, and Rajanikanth Madabushi
- Subjects
medicine.medical_specialty ,Advisory committee ,Advisory Committees ,030226 pharmacology & pharmacy ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,law ,Medicine ,Pharmacology (medical) ,Drug Dosage Calculations ,Dosing ,Multiple Chronic Conditions ,Pharmaceutical sciences ,Intensive care medicine ,Pharmacology ,Clinical Trials as Topic ,Clinical pharmacology ,business.industry ,United States Food and Drug Administration ,medicine.disease ,United States ,Clinical trial ,Drug development ,030220 oncology & carcinogenesis ,Area Under Curve ,Pharmacology, Clinical ,Kidney Diseases ,business ,Kidney disease ,Half-Life - Abstract
Patients with multiple chronic conditions, including more advanced chronic kidney disease (CKD), are often excluded from clinical trials, creating challenges in deriving appropriate dosing information and labeling. This article summarizes the May 7th , 2019 U.S. Food and Drug Administration Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting, which solicited expert opinions on how to enroll patients with more advanced CKD into clinical trials as well as the assumptions behind and different approaches of exposure-matching.
- Published
- 2020
31. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology
- Author
-
Yuching Yang, Manuela Grimstein, Shiew-Mei Huang, Jianghong Fan, Yaning Wang, Hao Zhu, Joseph A. Grillo, and Xinyuan Zhang
- Subjects
Physiologically based pharmacokinetic modelling ,medicine.medical_specialty ,Decision Making ,030226 pharmacology & pharmacy ,Models, Biological ,law.invention ,Food and drug administration ,03 medical and health sciences ,0302 clinical medicine ,Cytochrome P-450 Enzyme System ,law ,Prescribing information ,Medicine ,Pharmacology (medical) ,Medical physics ,Computer Simulation ,Drug Interactions ,Pharmacokinetics ,Drug Approval ,Pharmacology ,Clinical pharmacology ,business.industry ,United States Food and Drug Administration ,United States ,030220 oncology & carcinogenesis ,Pharmacology, Clinical ,business - Abstract
Since 2016, results from physiologically based pharmacokinetic (PBPK) analyses have been routinely found in the clinical pharmacology section of regulatory applications submitted to the US Food and Drug Administration (FDA). In 2018, the Food and Drug Administration's Office of Clinical Pharmacology published a commentary summarizing the application of PBPK modeling in the submissions it received between 2008 and 2017 and its impact on prescribing information. In this commentary, we provide an update on the application of PBPK modeling in submissions received between 2018 and 2019 and highlight a few notable examples.
- Published
- 2020
32. Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019
- Author
-
Xinyuan Zhang, Nan Zheng, Shiew-Mei Huang, Jiang Liu, Qi Liu, Jianghong Fan, Kellie S. Reynolds, Yuching Yang, Yaning Wang, Kimberly Bergman, and Hao Zhu
- Subjects
0301 basic medicine ,Microbiology (medical) ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030106 microbiology ,Pharmacology ,030226 pharmacology & pharmacy ,Antiviral Agents ,03 medical and health sciences ,0302 clinical medicine ,In vivo ,Extracellular ,Medicine ,Humans ,Dosing ,business.industry ,SARS-CoV-2 ,Brief Report ,COVID-19 ,Translation (biology) ,Hydroxychloroquine ,In vitro ,COVID-19 Drug Treatment ,Infectious Diseases ,AcademicSubjects/MED00290 ,antiviral activity ,business ,medicine.drug - Abstract
Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine. In vitro 50%/90% maximal effective concentration values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration, which is similar to the free plasma hydroxychloroquine concentration.
- Published
- 2020
33. Systematic Review of Device Parameters and Design of Studies Bridging Biologic-Device Combination Products Using Prefilled Syringes and Autoinjectors
- Author
-
Ping Hu, Issam Zineh, Jeffery Florian, Yow-Ming C Wang, Ping Ji, Jie Wang, Katherine Shatzer, Alan M Stevens, Shiew-Mei Huang, and Jacqueline Gertz
- Subjects
Male ,medicine.medical_specialty ,Bridging (networking) ,Drug Compounding ,Injections, Subcutaneous ,Pharmacology toxicology ,Pharmaceutical Science ,Bioequivalence ,030226 pharmacology & pharmacy ,law.invention ,03 medical and health sciences ,Drug Delivery Systems ,0302 clinical medicine ,law ,Combination Product ,Injection site ,Humans ,Medicine ,Tissue Distribution ,Medical physics ,Device parameters ,Biological Products ,Clinical pharmacology ,Viscosity ,business.industry ,Syringes ,Comparability ,Equipment Design ,Therapeutic Equivalency ,Needles ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Biologic-device combination products using prefilled syringes (PFSs) and autoinjectors (AIs) are popular for biological products administered subcutaneously. Pharmacokinetic (PK) comparability studies commonly provide the scientific data to support introduction of AI presentations via bridging with PFS. A survey of biological products approved by FDA's Center for Drug Evaluation and Research identified 17 biologics license applications (BLAs) with both PFS and AI presentations for subcutaneous (SC) administration, including 16 approved on February 1, 2018, and one with AI presentation under review. A systematic review on the device parameters and the PK comparability studies bridging the two presentations was conducted. Subsequently, whether device parameters or the PK study design may have influenced the PK comparability study results was evaluated. The reported device parameters for AI and PFS are generally consistent across BLAs, whereas the approach to assess PK comparability varied, including the study design. Most PK comparability studies met bioequivalence (BE) criteria. Upon inspection of the studies that did not meet BE criteria, injection depth of AI and the injection site for either AI or PFS were identified as potential influencing factors to the outcome of PK comparability study. This study represents an initial attempt to identify the potential influencing factors on device bridging, including the characteristics of the device and the clinical pharmacology study. These findings may inform the combination product development strategy, specifically design considerations for device and PK comparability studies.
- Published
- 2020
34. Metformin Disrupts Bile Acid Efflux by Repressing Bile Salt Export Pump Expression
- Author
-
Brandy Garzel, James E. Polli, Tao Hu, Scott Heyward, Shiew-Mei Huang, Lei Zhang, Linhao Li, Yuanfu Lu, Jean-Pierre Raufman, and Hongbing Wang
- Subjects
medicine.drug_class ,Pharmaceutical Science ,Repressor ,Pharmacology ,Article ,Cell Line ,Bile Acids and Salts ,Cholestasis ,medicine ,Bile ,Humans ,Pharmacology (medical) ,Psychological repression ,ATP Binding Cassette Transporter, Subfamily B, Member 11 ,Regulation of gene expression ,Bile acid ,Chemistry ,Organic Chemistry ,Biological Transport ,medicine.disease ,Bile Salt Export Pump ,Metformin ,Liver ,Hepatocytes ,Molecular Medicine ,Efflux ,Biotechnology ,medicine.drug - Abstract
PURPOSE: The bile salt export pump (BSEP), a key player in hepatic bile acid clearance, has been the center of research on drug-induced cholestasis. However, such studies focus primarily on the direct inhibition of BSEP, often overlooking the potential impact of transcriptional repression. This work aims to explore the disruption of bile acid efflux caused by drug-induced BSEP repression. METHODS: BSEP activity was analyzed in human primary hepatocytes (HPH) using a traditional biliary-clearance experiment and a modified efflux assay, which includes a 72-h pretreatment prior to efflux measurement. Relative mRNA and protein expressions were examined by RT-PCR and Western blotting, respectively. RESULTS: Metformin concentration-dependently repressed BSEP expression in HPH. Although metformin did not directly inhibit BSEP activity, longer metformin exposure reduced BSEP transport function in HPH by down-regulating BSEP expression. BSEP repression by metformin was found to be AMP-activated protein kinase-independent. Additional screening of 10 reported cholestatic non-BSEP inhibitors revealed that the anti-cancer drug tamoxifen also markedly repressed BSEP expression and reduced BSEP activity in HPH. CONCLUSIONS: Repression of BSEP alone is sufficient to disrupt hepatic bile acid efflux. Metformin and tamoxifen appear to be prototypes of a class of BSEP repressors that may cause drug-induced cholestasis through gene repression instead of direct BSEP inhibition.
- Published
- 2020
35. Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics
- Author
-
Sook Wah Yee, Ronald M. Krauss, Jashvant D. Unadkat, Kathleen M. Giacomini, Thao P. Do, Yuichi Sugiyama, Shiew-Mei Huang, and Hiroyuki Kusuhara
- Subjects
Pharmacology ,Extramural ,Pharmaceutical Research ,Library science ,Pharmacology and Pharmaceutical Sciences ,030226 pharmacology & pharmacy ,03 medical and health sciences ,Good Health and Well Being ,0302 clinical medicine ,Drug development ,Drug Development ,Pharmacogenetics ,030220 oncology & carcinogenesis ,Political science ,Pharmacogenomics ,Humans ,Pharmacology (medical) ,Cooperative behavior ,Pharmacology & Pharmacy ,Cooperative Behavior - Abstract
Author(s): Yee, Sook Wah; Do, Thao P; Huang, Shiew-Mei; Krauss, Ronald M; Kusuhara, Hiroyuki; Sugiyama, Yuichi; Unadkat, Jashvant D; Giacomini, Kathleen M
- Published
- 2020
36. A Novel Physiologically Based Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations
- Author
-
Aleksandra Galetin, Ping Zhao, Lei Zhang, Amin Rostami-Hodjegan, Vikram Arya, Xinning Yang, Daniel Scotcher, and Shiew-Mei Huang
- Subjects
Proteome ,Endogenous biomarker ,Renal function ,Bioinformatics ,Kidney ,Models, Biological ,Permeability ,Article ,Kidney Tubules, Proximal ,chemistry.chemical_compound ,medicine ,Humans ,Pharmacology (medical) ,Model development ,Pharmacokinetics ,Independent data ,Creatinine ,business.industry ,Research ,lcsh:RM1-950 ,Organic Cation Transporter 2 ,Disposition ,Articles ,PBPK Model ,Transporters ,Renal Elimination ,medicine.anatomical_structure ,lcsh:Therapeutics. Pharmacology ,HEK293 Cells ,chemistry ,Pharmaceutical Preparations ,Modeling and Simulation ,Renal physiology ,Drug Monitoring ,business ,Biomarkers ,Renal transporters ,Glomerular Filtration Rate - Abstract
Creatinine is the most common clinical biomarker of renal function. As a substrate for renal transporters, its secretion is susceptible to inhibition by drugs, resulting in transient increase in serum creatinine and false impression of damage to kidney. Novel physiologically based models for creatinine were developed here and (dis)qualified in a stepwise manner until consistency with clinical data. Data from a matrix of studies were integrated, including systems data (common to all models), proteomics-informed in vitro-in vivo extrapolation of all relevant transporter clearances, exogenous administration of creatinine (to estimate endogenous synthesis rate), and inhibition of different renal transporters (11 perpetrator drugs considered for qualification during creatinine model development and verification on independent data sets). The proteomics-informed bottom-up approach resulted in the underprediction of creatinine renal secretion. Subsequently, creatinine-trimethoprim clinical data were used to inform key model parameters in a reverse translation manner, highlighting best practices and challenges for middle-out optimization of mechanistic models.
- Published
- 2019
37. A regulatory science viewpoint on botanical–drug interactions
- Author
-
Shiew-Mei Huang and Manuela Grimstein
- Subjects
Herb-Drug Interactions ,lcsh:TX341-641 ,Scientific literature ,030226 pharmacology & pharmacy ,03 medical and health sciences ,0302 clinical medicine ,Health care ,Humans ,Regulatory science ,Lack of knowledge ,Drug Labeling ,Pharmacology ,Perceived safety ,business.industry ,lcsh:RM1-950 ,Liability ,Drug interaction ,lcsh:Therapeutics. Pharmacology ,Pharmaceutical Preparations ,Botanical drug ,030220 oncology & carcinogenesis ,Engineering ethics ,Business ,lcsh:Nutrition. Foods and food supply ,Drugs, Chinese Herbal ,Food Science - Abstract
There is a continued predisposition of concurrent use of drugs and botanical products. Consumers often self-administer botanical products without informing their health care providers. The perceived safety of botanical products with lack of knowledge of the interaction potential poses a challenge for providers and both efficacy and safety concerns for patients. Botanical–drug combinations can produce untoward effects when botanical constituents modulate drug metabolizing enzymes and/or transporters impacting the systemic or tissue exposure of concomitant drugs. Examples of pertinent scientific literature evaluating the interaction potential of commonly used botanicals in the US are discussed. Current methodologies that can be applied to advance our efforts in predicting drug interaction liability is presented. This review also highlights the regulatory science viewpoint on botanical–drug interactions and labeling implications. Keywords: Drug interaction, Botanical product, St. John's wort, Fruit juices, Regulatory science
- Published
- 2018
38. Model‐Informed Drug Development: A Regulatory Perspective on Progress
- Author
-
Rajanikanth Madabushi, David G. Strauss, Yaning Wang, Shiew-Mei Huang, Issam Zineh, and Hao Zhu
- Subjects
Pharmacology ,Knowledge management ,Drug Industry ,United States Food and Drug Administration ,business.industry ,Perspective (graphical) ,MEDLINE ,Efficiency, Organizational ,Models, Biological ,United States ,Drug Development ,Drug development ,Humans ,Computer Simulation ,Pharmacology (medical) ,Cooperative behavior ,Sociology ,Cooperative Behavior ,business - Published
- 2019
39. Considerations for Biologic Product Drug–Drug Interactions: A Regulatory Perspective
- Author
-
Rajanikanth Madabushi, Sarah J. Schrieber, Xiaofei Wang, Shiew-Mei Huang, Yow-Ming C Wang, Sharonjit Sagoo, Issam Zineh, and Elimika Pfuma‐Fletcher
- Subjects
Pharmacology ,Drug ,Biological Products ,Knowledge management ,United States Food and Drug Administration ,business.industry ,media_common.quotation_subject ,Perspective (graphical) ,MEDLINE ,United States ,Humans ,Drug Interactions ,Pharmacology (medical) ,Business ,Product (category theory) ,Biosimilar Pharmaceuticals ,media_common - Published
- 2019
40. Commentary on Fit-For-Purpose Models for Regulatory Applications
- Author
-
Shiew-Mei Huang and Yaning Wang
- Subjects
Value (ethics) ,Prescription Drugs ,Clinical pharmacology ,Management science ,Computer science ,Pharmaceutical Science ,02 engineering and technology ,021001 nanoscience & nanotechnology ,Models, Biological ,030226 pharmacology & pharmacy ,Model complexity ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Drug Development ,Drug development ,law ,Pharmacology, Clinical ,Humans ,Computer Simulation ,Pharmacokinetics ,Regulatory science ,0210 nano-technology ,Prescription Drug User Fee Act - Abstract
Model-based analyses have been applied to influence various drug development and regulatory decisions in the last 2 decades. Applied models range from empirical models to highly complex mechanistic models. "Fit-for-purpose" has been the principle to determine the level of model complexity. While numerous case studies have been published to highlight the impact and value of model-based analyses, more experience and lessons are being accumulated to address new challenges and create more opportunities. The inclusion of Model-Informed Drug Development in the Prescription Drug User Fee Act (PDUFA) VI represents a new landmark for the field of quantitative clinical pharmacology.
- Published
- 2019
41. Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
- Author
-
Thomas D. Nolin, Aleksandra Galetin, Micheline Piquette-Miller, Ming Liang Tan, Lei Zhang, Ping Zhao, Kenta Yoshida, and Shiew-Mei Huang
- Subjects
medicine.medical_specialty ,Organic Anion Transporters ,Renal function ,CYP2C19 ,Pharmacology ,030226 pharmacology & pharmacy ,Cytochrome P-450 CYP2C8 ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Cytochrome P-450 CYP1A2 ,Internal medicine ,medicine ,Cytochrome P-450 Enzyme Inhibitors ,Humans ,Pharmacology (medical) ,Renal Insufficiency, Chronic ,CYP2C8 ,CYP2C9 ,Cytochrome P-450 CYP2C9 ,CYP3A4 ,business.industry ,Research ,CYP1A2 ,Articles ,medicine.disease ,3. Good health ,Cytochrome P-450 CYP2C19 ,Endocrinology ,030220 oncology & carcinogenesis ,business ,Kidney disease - Abstract
Our recent studies have shown that chronic kidney disease (CKD) affects the pharmacokinetics (PKs) of cytochrome P450 (CYP)2D6-metabolized drugs, whereas effects were less evident on CYP3A4/5. Therefore, the effect of CKD on the disposition of CYP1A2-metabolized, CYP2C8-metabolized, CYP2C9-metabolized, CYP2C19-metabolized, and organic anion-transporting polypeptide (OATP)-transported drugs was investigated. We identified dedicated CKD studies with 6, 5, 6, 4, and 12 "model" substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP, respectively. Our analyses suggest that clearance of OATP substrates decreases as kidney function declines. Similar trends were seen for CYP2C8; but overlap between some CYP2C8 and OATP substrates highlights that their interplay needs further investigation. In contrast, the effect of CKD on CYP1A2, CYP2C9, and CYP2C19 was variable and modest compared to CYP2C8 and OATP. This improved understanding of elimination-pathway-dependency in CKD is important to inform the need and conduct of PK studies in these patients for nonrenally eliminated drugs.
- Published
- 2017
42. Role of CYP3A in Oral Contraceptives Clearance
- Author
-
Jihong Shon, Lei Zhang, LaiMing Lee, Chongwoo Yu, Li Li, Doanh Tran, Myong-Jin Kim, Shiew-Mei Huang, and Nan Zhang
- Subjects
0301 basic medicine ,Drug ,CYP3A4 ,CYP3A ,business.industry ,General Neuroscience ,media_common.quotation_subject ,Combined oral contraceptives ,Investigational New Drug ,General Medicine ,Pharmacology ,Drug interaction ,030226 pharmacology & pharmacy ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Liver metabolism ,Medicine ,General Pharmacology, Toxicology and Pharmaceutics ,business ,media_common - Abstract
We evaluated the relative contribution of CYP3A in the overall clearance of commonly used combined oral contraceptives (COCs) based on the results of clinical DDI studies in the literature and new drug applications (NDAs). The results revealed a limited role of CYP3A4 in the metabolism of COC components. Characterization of inhibition or induction spectrum of perpetrators on non‐CYP3A pathways might also be crucial in predicting drug interaction potential of an investigational new drug with COCs.
- Published
- 2017
43. The Effect of Uremic Solutes on the Organic Cation Transporter 2
- Author
-
Chia Hsiang Hsueh, Kit Wun Kathy Cheung, Timothy W. Meyer, Lei Zhang, Shiew-Mei Huang, Kathleen M. Giacomini, and Ping Zhao
- Subjects
Indoles ,Organic anion transporter 1 ,Pharmaceutical Science ,Renal function ,Glucuronates ,Pharmacology ,Kidney ,urologic and male genital diseases ,030226 pharmacology & pharmacy ,Methylamines ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacokinetics ,Malondialdehyde ,medicine ,Humans ,Renal Insufficiency, Chronic ,Homocysteine ,Toxins, Biological ,Uremia ,Organic cation transport proteins ,Glutathione Disulfide ,biology ,Chemistry ,Organic Cation Transporter 2 ,Biological Transport ,medicine.disease ,Metformin ,HEK293 Cells ,Biochemistry ,030220 oncology & carcinogenesis ,Renal physiology ,biology.protein ,Glutathione disulfide ,Dimethylamines ,Glomerular Filtration Rate ,Kidney disease ,medicine.drug - Abstract
Chronic kidney disease (CKD) is characterized by the accumulation of uremic solutes; however, little is known about how these solutes affect drug absorption and disposition. The goal of this study is to evaluate the effect of uremic solutes on the organic cation transporter, OCT2, which plays a key role in the renal secretion of many basic drugs. As a second goal, we reviewed the literature to determine whether there was evidence for the effect of CKD on the renal secretion of basic drugs. We first screened 72 uremic solutes as inhibitors of [14C]-labeled metformin uptake by OCT2. Seven were identified as inhibitors and 3 of them were determined to be clinically relevant. Of the 7 solutes, dimethylamine, malondialdehyde, trimethylamine, homocysteine, indoxyl-β-d-glucuronide, and glutathione disulfide were novel OCT2 inhibitors. For 6 drugs that are known OCT2 substrates, both secretory clearance and glomerular filtration rate declined in parallel with progression of CKD from stage 2 to 4, suggesting that selective effects of uremic solutes on net tubular secretion of organic cations do not occur. Further clinical studies are warranted with a broader range of OCT2 substrates to determine whether CKD may differentially affect tubular secretion of drugs especially in patients with advanced CKD.
- Published
- 2017
44. Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist
- Author
-
Hiroshi Suzuki, Shiew-Mei Huang, Tetsuya Terasaki, Hartmut Derendorf, Margareta Hammarlund-Udenaes, Hiroyuki Kusuhara, Per Artursson, K. Sandy Pang, Amin Rostami-Hodjegan, and R. Scott Obach
- Subjects
Pharmacology ,0301 basic medicine ,Chemistry, Pharmaceutical ,media_common.quotation_subject ,Pharmaceutical Science ,Art history ,Biological Transport ,Art ,History, 21st Century ,030226 pharmacology & pharmacy ,03 medical and health sciences ,Drug Delivery Systems ,030104 developmental biology ,0302 clinical medicine ,Japan ,media_common - Abstract
Professor Yuichi Sugiyama : A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist
- Published
- 2017
45. In Vitro–In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug–Drug Interactions—Overview of Basic Prediction Methods
- Author
-
Darrell R. Abernethy, Ping Zhao, Dinko Rekić, Kellie S. Reynolds, Kenta Yoshida, Aleksandra Galetin, Lei Zhang, and Shiew-Mei Huang
- Subjects
Drug ,Drug interaction ,media_common.quotation_subject ,Pharmaceutical Science ,Computational biology ,Pharmacology ,Models, Biological ,Risk Assessment ,030226 pharmacology & pharmacy ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,immune system diseases ,parasitic diseases ,Guidance/Guideline ,Animals ,Humans ,Drug Interactions ,heterocyclic compounds ,Dosing ,In vitro in vivo ,Cytochrome P450s ,ADME ,media_common ,Chemistry ,Membrane Transport Proteins ,virus diseases ,Transporter ,Drugs, Investigational ,biochemical phenomena, metabolism, and nutrition ,Regulatory ,Membrane transport/transporters ,Drug development ,030220 oncology & carcinogenesis - Abstract
Evaluation of drug–drug interaction (DDI) risk is vital to establish benefit–risk profiles of investigational new drugs during drug development. In vitro experiments are routinely conducted as an important first step to assess metabolism- and transporter-mediated DDI potential of investigational new drugs. Results from these experiments are interpreted, often with the aid of in vitro – in vivo extrapolation methods, to determine whether and how DDI should be evaluated clinically to provide the basis for proper DDI management strategies, including dosing recommendations, alternative therapies, or contraindications under various DDI scenarios and in different patient population. This article provides an overview of currently available in vitro experimental systems and basic in vitro – in vivo extrapolation methodologies for metabolism- and transporter-mediated DDIs.
- Published
- 2017
46. Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells
- Author
-
Rena G. Lapidus, Hongbing Wang, Zhihui Li, Shiew-Mei Huang, Paul Shapiro, Lei Zhang, Daochuan Li, and Eun Yong Choi
- Subjects
Hepatoblastoma ,0301 basic medicine ,ATP citrate lyase ,Mice, Nude ,Biochemistry ,Energy homeostasis ,03 medical and health sciences ,Cell Line, Tumor ,Animals ,Humans ,Editors' Picks ,RNA, Small Interfering ,Protein kinase A ,Molecular Biology ,Mechanistic target of rapamycin ,Tumor Stem Cell Assay ,Cell Proliferation ,Symporters ,biology ,Kinase ,Cell growth ,Liver Neoplasms ,Cell Biology ,Xenograft Model Antitumor Assays ,Neoplasm Proteins ,Specific Pathogen-Free Organisms ,Tumor Burden ,Solute carrier family ,Gene Expression Regulation, Neoplastic ,RNAi Therapeutics ,030104 developmental biology ,biology.protein ,Cancer research ,Female ,RNA Interference ,Energy Metabolism ,Intracellular - Abstract
The solute carrier family 13 member 5 (SLC13A5), a sodium-coupled citrate transporter, plays a key role in importing citrate from the circulation into liver cells. Recent evidence has revealed that SLC13A5 deletion protects mice from high-fat diet–induced hepatic steatosis and that mutation of the SLC13A5 orthologues in Drosophila melanogaster and Caenorhabditis elegans promotes longevity. However, despite the emerging importance of SLC13A5 in energy homeostasis, whether perturbation of SLC13A5 affects the metabolism and malignancy of hepatocellular carcinoma is unknown. Here, we sought to determine whether SLC13A5 regulates hepatic energy homeostasis and proliferation of hepatoma cells. RNAi-mediated silencing of SLC13A5 expression in two human hepatoma cell lines, HepG2 and Huh7, profoundly suppressed cell proliferation and colony formation, and induced cell cycle arrest accompanied by increased expression of cyclin-dependent kinase inhibitor p21 and decreased expression of cyclin B1. Furthermore, such suppressive effects were also observed on the growth of HepG2 cell-derived xenografts expressing SLC13A5-shRNA in nude mice. Metabolically, knockdown of SLC13A5 in HepG2 and Huh7 cells was associated with a decrease in intracellular levels of citrate, the ratio of ATP/ADP, phospholipid content, and ATP citrate lyase expression. Moreover, both in vitro and in vivo assays demonstrated that SLC13A5 depletion promotes activation of the AMP-activated protein kinase, which was accompanied by deactivation of oncogenic mechanistic target of rapamycin signaling. Together, our findings expand the role of SLC13A5 from facilitating hepatic energy homeostasis to influencing hepatoma cell proliferation and suggest a potential role of SLC13A5 in the progression of human hepatocellular carcinoma.
- Published
- 2017
47. P72 - Quantitative prediction of CYP3A4 and CYP3A5-mediated drug drug interactions
- Author
-
Raj Vuppalanchi, J. Hilligoss, Shiew-Mei Huang, Stephen D. Hall, Yingying Guo, Gemma L. Dickinson, and Aroonrut Lucksiri
- Subjects
Pharmacology ,Drug ,CYP3A4 ,business.industry ,media_common.quotation_subject ,Pharmaceutical Science ,Medicine ,Pharmacology (medical) ,business ,CYP3A5 ,media_common - Published
- 2020
48. Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation
- Author
-
Jeffry Florian, Yaning Wang, Tina M. Morrison, Yuching Yang, Issam Zineh, Million A. Tegenge, Colleen Kuemmel, Shiew-Mei Huang, Xinyuan Zhang, and Hao Zhu
- Subjects
Physiologically based pharmacokinetic modelling ,Computational model ,Computer science ,Pharmacokinetic modeling ,lcsh:RM1-950 ,Decision Making ,White Paper ,Models, Biological ,Risk Assessment ,White Papers ,Model validation ,Variety (cybernetics) ,lcsh:Therapeutics. Pharmacology ,Drug development ,Risk analysis (engineering) ,Drug Development ,Modeling and Simulation ,Credibility ,Humans ,Pharmacology (medical) ,Computer Simulation ,Pharmacokinetics ,Software verification and validation - Abstract
The use of computational models in drug development has grown during the past decade. These model-informed drug development (MIDD) approaches can inform a variety of drug development and regulatory decisions. When used for regulatory decision making, it is important to establish that the model is credible for its intended use. Currently, there is no consensus on how to establish and assess model credibility, including the selection of appropriate verification and validation activities. In this article, we apply a risk-informed credibility assessment framework to physiologically-based pharmacokinetic modeling and simulation and hypothesize this evidentiary framework may also be useful for evaluating other MIDD approaches. We seek to stimulate a scientific discussion around this framework as a potential starting point for uniform assessment of model credibility across MIDD. Ultimately, an overarching framework may help to standardize regulatory evaluation across therapeutic products (i.e., drugs and medical devices).
- Published
- 2019
49. Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters
- Author
-
Kit Wun Kathy Cheung, Shiew-Mei Huang, Saskia N. de Wildt, Gilbert J. Burckart, Bianca D van Groen, Lei Zhang, and Pediatric Surgery
- Subjects
Drug ,Physiologically based pharmacokinetic modelling ,Ontogeny ,media_common.quotation_subject ,Bioinformatics ,Kidney ,030226 pharmacology & pharmacy ,Models, Biological ,Article ,03 medical and health sciences ,0302 clinical medicine ,All institutes and research themes of the Radboud University Medical Center ,Pharmacokinetics ,Drug Development ,Medicine ,Humans ,Pharmacology (medical) ,Prescription Drug User Fee Act ,Child ,media_common ,Pharmacology ,business.industry ,Infant, Newborn ,Infant ,Membrane Transport Proteins ,Disposition ,Pediatric drug ,Drug development ,Liver ,Pharmaceutical Preparations ,030220 oncology & carcinogenesis ,Child, Preschool ,Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] ,business - Abstract
Developmental changes in the biological processes involved in the disposition of drugs, such as membrane transporter expression and activity, may alter the drug exposure and clearance in pediatric patients. Physiologically based pharmacokinetic (PBPK) models take these age-dependent changes into account and may be used to predict drug exposure in children. As a result, this mechanistic-based tool has increasingly been applied to improve pediatric drug development. Under the Prescription Drug User Fee Act VI, the US Food and Drug Administration has committed to facilitate the advancement of PBPK modeling in the drug application review process. Yet, significant knowledge gaps on developmental biology still exist, which must be addressed to increase the confidence of prediction. Recently, more data on ontogeny of transporters have emerged and supplied a missing piece of the puzzle. This article highlights the recent findings on the ontogeny of transporters specifically in the intestine, liver, and kidney. It also provides a case study that illustrates the utility of incorporating this information in predicting drug exposure in children using a PBPK approach. Collaborative work has greatly improved the understanding of the interplay between developmental physiology and drug disposition. Such efforts will continue to be needed to address the remaining knowledge gaps to enhance the application of PBPK modeling in drug development for children.
- Published
- 2019
50. What Does It Take to Transform Real-World Data Into Real-World Evidence?
- Author
-
Shiew-Mei Huang and Anuradha Ramamoorthy
- Subjects
Pharmacology ,Research design ,Big Data ,Computer science ,business.industry ,Big data ,MEDLINE ,Real world evidence ,Global Health ,Data science ,Decision Support Techniques ,Research Design ,Evidence-Based Practice ,Practice Guidelines as Topic ,Global health ,Information system ,Product Surveillance, Postmarketing ,Humans ,Pharmacology (medical) ,Diffusion of Innovation ,business ,Real world data ,Introductory Journal Article ,Information Systems - Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.